PT2872488T - Formas cristalinas do ácido [(4-hidroxi-1-metil-7-fenoxi-isoquinolina-3-carbonil)amino]acético inibidor da prolil-hidroxilase - Google Patents
Formas cristalinas do ácido [(4-hidroxi-1-metil-7-fenoxi-isoquinolina-3-carbonil)amino]acético inibidor da prolil-hidroxilaseInfo
- Publication number
- PT2872488T PT2872488T PT13740185T PT13740185T PT2872488T PT 2872488 T PT2872488 T PT 2872488T PT 13740185 T PT13740185 T PT 13740185T PT 13740185 T PT13740185 T PT 13740185T PT 2872488 T PT2872488 T PT 2872488T
- Authority
- PT
- Portugal
- Prior art keywords
- crystalline forms
- prolyl hydroxylase
- hydroxylase inhibitor
- inhibitor
- prolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261672191P | 2012-07-16 | 2012-07-16 | |
US201361768297P | 2013-02-22 | 2013-02-22 | |
US201361832566P | 2013-06-07 | 2013-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2872488T true PT2872488T (pt) | 2018-11-22 |
Family
ID=48857025
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT181896077T PT3470397T (pt) | 2012-07-16 | 2013-07-15 | Formas cristalinas de um inibidor da prolil-hidroxilase |
PT13740185T PT2872488T (pt) | 2012-07-16 | 2013-07-15 | Formas cristalinas do ácido [(4-hidroxi-1-metil-7-fenoxi-isoquinolina-3-carbonil)amino]acético inibidor da prolil-hidroxilase |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT181896077T PT3470397T (pt) | 2012-07-16 | 2013-07-15 | Formas cristalinas de um inibidor da prolil-hidroxilase |
Country Status (27)
Country | Link |
---|---|
US (5) | US9115085B2 (pt) |
EP (3) | EP3470397B1 (pt) |
JP (2) | JP6491093B2 (pt) |
KR (4) | KR20220164068A (pt) |
CN (9) | CN104684897A (pt) |
AU (1) | AU2013290438C1 (pt) |
BR (1) | BR112015001101A2 (pt) |
CA (1) | CA2879242C (pt) |
CY (2) | CY1120805T1 (pt) |
DK (2) | DK3470397T3 (pt) |
ES (2) | ES2905898T3 (pt) |
FR (1) | FR22C1030I1 (pt) |
HK (1) | HK1243409A1 (pt) |
HR (2) | HRP20220182T1 (pt) |
HU (2) | HUE041458T2 (pt) |
IL (1) | IL236626B (pt) |
IN (1) | IN2015KN00262A (pt) |
LT (3) | LT3470397T (pt) |
MX (1) | MX355428B (pt) |
MY (1) | MY182428A (pt) |
NZ (1) | NZ704662A (pt) |
PL (2) | PL2872488T3 (pt) |
PT (2) | PT3470397T (pt) |
RS (2) | RS57795B1 (pt) |
SG (3) | SG10201700873UA (pt) |
SI (2) | SI3470397T1 (pt) |
WO (1) | WO2014014835A2 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1644336T3 (da) | 2003-06-06 | 2011-05-09 | Fibrogen Inc | Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin |
WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
WO2014014834A1 (en) | 2012-07-16 | 2014-01-23 | Fibrogen, Inc. | Process for making isoquinoline compounds |
EP3470397B1 (en) * | 2012-07-16 | 2021-12-29 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
ES2786924T3 (es) | 2013-06-06 | 2020-10-14 | Fibrogen Inc | Formulaciones farmacéuticas que comprenden un inhibidor de hidroxilasa del HIF |
CN103694172A (zh) * | 2013-12-26 | 2014-04-02 | 辽宁亿灵科创生物医药科技有限公司 | 含氮杂芳基化合物的衍生物 |
WO2016045125A1 (en) | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
CN104892509B (zh) * | 2015-06-04 | 2018-03-09 | 苏州明锐医药科技有限公司 | 诺得司他的制备方法 |
CN106916105A (zh) * | 2015-12-28 | 2017-07-04 | 徐州万邦金桥制药有限公司 | 一种纯化可博美的方法 |
WO2017143131A1 (en) * | 2016-02-19 | 2017-08-24 | Cornell University | Hif-stabilization and prevention of hyperoxia-induced neonatal lung disease |
CN106187888A (zh) * | 2016-07-18 | 2016-12-07 | 江苏德源药业股份有限公司 | Fg‑4592单晶及其制备方法 |
CN108017583B (zh) * | 2016-11-01 | 2021-04-06 | 徐州万邦金桥制药有限公司 | 一种可博美的制备方法 |
CN107382986B (zh) * | 2017-08-02 | 2022-09-20 | 江苏艾立康医药科技有限公司 | 4-羟基-1-甲基异喹啉衍生物及其在增加内源性***中的用途 |
JP2020530473A (ja) * | 2017-08-11 | 2020-10-22 | ドクター レディズ ラボラトリーズ リミテッド | ロキサデュスタットの多形および共結晶 |
WO2019042485A1 (en) | 2017-08-30 | 2019-03-07 | Zentiva, K.S. | FORMS IN THE STRONG STATE OF ROXADUSTAT |
JP7144510B2 (ja) * | 2017-09-04 | 2022-09-29 | サンド・アクチエンゲゼルシヤフト | 経口投与可能なhifプロリルヒドロキシラーゼ阻害剤の共結晶 |
CN111978226B (zh) | 2018-06-05 | 2022-03-04 | 沈阳化工大学 | 一种三氟乙基硫醚(亚砜)取代苯类化合物及其用途 |
CN111320583A (zh) * | 2018-12-14 | 2020-06-23 | 广东东阳光药业有限公司 | 诺德司他新晶型及其制备方法 |
CN109369525A (zh) * | 2018-12-29 | 2019-02-22 | 安礼特(上海)医药科技有限公司 | 罗沙司它的新晶型及其制备方法 |
WO2020217190A1 (en) * | 2019-04-26 | 2020-10-29 | Dr. Reddy’S Laboratories Limited | Process for the purification of roxadustat |
CN112679428A (zh) * | 2019-10-17 | 2021-04-20 | 罗欣药业(上海)有限公司 | 罗沙司他新晶型及其制备方法 |
JP2022553706A (ja) | 2019-10-22 | 2022-12-26 | ▲蘇▼州科睿思制▲葯▼有限公司 | 低酸素誘導因子-プロリルヒドロキシラーゼ阻害剤の結晶形 |
CN110721185B (zh) * | 2019-11-13 | 2022-04-12 | 南京市儿童医院 | 罗沙司他用于心肌保护的用途 |
CN112961107A (zh) * | 2019-12-13 | 2021-06-15 | 罗欣药业(上海)有限公司 | 罗沙司他的晶型及其制备方法 |
US20230190731A1 (en) * | 2020-03-17 | 2023-06-22 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
CN111205224B (zh) * | 2020-04-22 | 2020-08-25 | 南京佰麦生物技术有限公司 | 一种罗沙司他水合物的晶型及其制备方法和应用 |
CN113754569A (zh) * | 2020-06-04 | 2021-12-07 | 四川国为制药有限公司 | 一种中间体化合物及其制备方法和用途 |
CN111533691A (zh) * | 2020-06-08 | 2020-08-14 | 重庆三圣实业股份有限公司 | 一种罗沙司他的制备方法 |
CN114057643B (zh) * | 2020-08-04 | 2023-02-28 | 成都苑东生物制药股份有限公司 | 一种罗沙司他共晶及其制备方法 |
CN112194624A (zh) * | 2020-11-18 | 2021-01-08 | 江苏豪森药业集团有限公司 | 一种异喹啉类化合物的晶型及其制备方法 |
CN112500344B (zh) * | 2020-11-18 | 2022-07-01 | 江苏豪森药业集团有限公司 | 罗沙司他晶型及其制备方法 |
CN113956200A (zh) * | 2021-12-16 | 2022-01-21 | 南京威凯尔生物医药科技有限公司 | 一种粒径控制的罗沙司他原料药的结晶工艺 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4036964A (en) | 1973-10-11 | 1977-07-19 | Beecham Group Limited | Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis |
US3989704A (en) | 1973-10-30 | 1976-11-02 | Sandoz, Inc. | 3-Substituted-4-aryl isoquinolines |
DE2818423A1 (de) | 1978-04-27 | 1979-11-08 | Hoechst Ag | Neue isochinolinderivate und verfahren zu ihrer herstellung |
DE3233424A1 (de) | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
US4558006A (en) | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
US4559403A (en) | 1983-05-19 | 1985-12-17 | Hoffmann-La Roche Inc. | Substituted isoquinolines |
US4584379A (en) | 1985-01-22 | 1986-04-22 | Merrell Dow Pharmaceuticals Inc. | Isoquinoline thromboxane synthetase inhibitors |
US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
US4822800A (en) | 1986-06-09 | 1989-04-18 | Ortho Pharmaceutical Corporation | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
DE59401923D1 (de) | 1993-11-02 | 1997-04-10 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
TW406076B (en) | 1993-12-30 | 2000-09-21 | Hoechst Ag | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
WO1996018616A1 (en) | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
ATE342262T1 (de) | 1996-11-27 | 2006-11-15 | Bristol Myers Squibb Pharma Co | Neue integrin rezeptor antagonisten |
DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
FR2779963A1 (fr) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
IT1302677B1 (it) | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
IT1315220B1 (it) * | 1999-12-13 | 2003-02-03 | Ipm Ind Plastica Monregalese | Telone di foglia pluristrato di materia plastica per pacciamature e/ocome barriera di contenimento di sostanze di trattamento in |
IT1320162B1 (it) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico. |
FI20002044A0 (fi) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
US20040146964A1 (en) | 2001-03-21 | 2004-07-29 | Maxwell Patrick Henry | Assays, methods and means |
WO2002101073A2 (en) | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc. | Aryl-benzimidazole compounds having antiinfective activity |
JP2005505507A (ja) | 2001-06-13 | 2005-02-24 | ジーンソフト ファーマシューティカルズ インコーポレイテッド | 抗感染活性を有するイソキノリン化合物 |
US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
EP2324834B1 (en) | 2001-12-06 | 2019-05-08 | Fibrogen, Inc. | Methods of Increasing Endogenous Erythropoietin (EPO) |
US8318703B2 (en) | 2001-12-06 | 2012-11-27 | Fibrogen, Inc. | Methods for improving kidney function |
US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
EA008196B1 (ru) | 2002-12-16 | 2007-04-27 | Киссеи Фармасьютикал Ко., Лтд. | Твердая лекарственная форма для перорального применения |
DK1644336T3 (da) | 2003-06-06 | 2011-05-09 | Fibrogen Inc | Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin |
US20060251638A1 (en) | 2003-06-06 | 2006-11-09 | Volkmar Guenzler-Pukall | Cytoprotection through the use of hif hydroxylase inhibitors |
US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
EP1646611A1 (en) | 2003-07-15 | 2006-04-19 | Merck & Co., Inc. | Hydroxypyridine cgrp receptor antagonists |
WO2005011696A1 (en) | 2003-08-01 | 2005-02-10 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
CA2531796A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
US7718797B2 (en) | 2004-03-16 | 2010-05-18 | Asahi Kasei Pharma Corporation | Fasudil-containing preparation and method of improving stability thereof |
WO2005118836A2 (en) | 2004-05-28 | 2005-12-15 | Fibrogen, Inc. | Hif prolyl hydroxylase activity assay |
GB2421013B (en) | 2004-12-10 | 2007-07-11 | Amcor Flexibles Europe As | Packaging with an openable top wall |
ATE513833T1 (de) | 2005-03-02 | 2011-07-15 | Fibrogen Inc | Thienopyridinverbindungen und verfahren zu ihrer verwendung |
WO2006133391A2 (en) | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
US8530404B2 (en) | 2005-06-15 | 2013-09-10 | Fibrogen, Inc. | Compounds and methods for treatment of cancer |
UA97349C2 (uk) | 2005-09-08 | 2012-02-10 | Х. Луннбэк А/С | Стійкі тверді склади сертиндолу |
EP2476669A1 (en) | 2006-01-27 | 2012-07-18 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
EP1991269A1 (en) | 2006-02-16 | 2008-11-19 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
JP5111491B2 (ja) | 2006-04-04 | 2013-01-09 | フィブロジェン, インコーポレイテッド | ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法 |
WO2007141743A2 (en) | 2006-06-06 | 2007-12-13 | Ranbaxy Laboratories Limited | A tablet dosage form comprising cetirizine and pseudoephedrine |
US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
JP5683058B2 (ja) | 2007-04-27 | 2015-03-11 | ニプロ株式会社 | 経口固形製剤及びその製造方法 |
DK2209501T3 (da) | 2007-10-12 | 2012-02-27 | Astrazeneca Ab | Zibotentan-sammensætning, der indeholder mannitol og mikrokrystallinsk cellulose |
WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
CN102264740B (zh) | 2008-08-20 | 2014-10-15 | 菲布罗根有限公司 | 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途 |
WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
JP5479949B2 (ja) | 2009-04-08 | 2014-04-23 | 株式会社東芝 | 測定装置、測定方法、及び二酸化炭素回収システム |
JP2010248106A (ja) | 2009-04-14 | 2010-11-04 | Dainippon Sumitomo Pharma Co Ltd | フィルムコーティング錠 |
JP2012176899A (ja) | 2009-05-19 | 2012-09-13 | Mitsubishi Tanabe Pharma Corp | 2−(1−ピペラジニル)−5−メチルベンゼンスルホン酸誘導体を含む注射用水溶液 |
US8339523B2 (en) | 2010-05-18 | 2012-12-25 | Kabushiki Kaisha Toshiba | Television apparatus and electronic apparatus |
CN101880914B (zh) | 2010-05-25 | 2012-09-12 | 中国科学院微电子研究所 | 利用等离子体浸没离子注入制备黑硅的方法 |
WO2012097331A1 (en) | 2011-01-13 | 2012-07-19 | Fibrogen, Inc. | Methods for increasing reticulocyte hemoglobin content |
CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
EP2734504B1 (en) * | 2011-07-22 | 2016-09-14 | Beijing Betta Pharmaceuticals Co., Ltd | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
US20140309256A1 (en) | 2011-11-09 | 2014-10-16 | Fibrogen, Inc. | Therapeutic Method |
WO2013134660A1 (en) | 2012-03-09 | 2013-09-12 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
WO2014014834A1 (en) * | 2012-07-16 | 2014-01-23 | Fibrogen, Inc. | Process for making isoquinoline compounds |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
EP3470397B1 (en) * | 2012-07-16 | 2021-12-29 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
DK2951159T3 (en) | 2013-01-24 | 2018-11-19 | Fibrogen Inc | CRYSTALLIC FORMS OF {[1-CYANO-5- (4-CHLORPHENOXY) -4-HYDROXY-ISOQUINOLIN-3-CARBONYL] -AMINO} ACETIC ACID |
ES2786924T3 (es) | 2013-06-06 | 2020-10-14 | Fibrogen Inc | Formulaciones farmacéuticas que comprenden un inhibidor de hidroxilasa del HIF |
-
2013
- 2013-07-15 EP EP18189607.7A patent/EP3470397B1/en active Active
- 2013-07-15 HU HUE13740185A patent/HUE041458T2/hu unknown
- 2013-07-15 BR BR112015001101A patent/BR112015001101A2/pt not_active Application Discontinuation
- 2013-07-15 CN CN201380037479.XA patent/CN104684897A/zh active Pending
- 2013-07-15 NZ NZ704662A patent/NZ704662A/en unknown
- 2013-07-15 SG SG10201700873UA patent/SG10201700873UA/en unknown
- 2013-07-15 SI SI201331973T patent/SI3470397T1/sl unknown
- 2013-07-15 CN CN201810750543.3A patent/CN109369524A/zh active Pending
- 2013-07-15 DK DK18189607.7T patent/DK3470397T3/da active
- 2013-07-15 PL PL13740185T patent/PL2872488T3/pl unknown
- 2013-07-15 EP EP13740185.7A patent/EP2872488B1/en active Active
- 2013-07-15 CN CN201710546619.6A patent/CN107382860A/zh active Pending
- 2013-07-15 PT PT181896077T patent/PT3470397T/pt unknown
- 2013-07-15 HU HUE18189607A patent/HUE057925T2/hu unknown
- 2013-07-15 CN CN201710546354.XA patent/CN107382859B/zh active Active
- 2013-07-15 MX MX2015000504A patent/MX355428B/es active IP Right Grant
- 2013-07-15 CA CA2879242A patent/CA2879242C/en active Active
- 2013-07-15 RS RS20181268A patent/RS57795B1/sr unknown
- 2013-07-15 PT PT13740185T patent/PT2872488T/pt unknown
- 2013-07-15 MY MYPI2015000129A patent/MY182428A/en unknown
- 2013-07-15 PL PL18189607T patent/PL3470397T3/pl unknown
- 2013-07-15 SG SG11201500236SA patent/SG11201500236SA/en unknown
- 2013-07-15 WO PCT/US2013/050539 patent/WO2014014835A2/en active Application Filing
- 2013-07-15 DK DK13740185.7T patent/DK2872488T3/en active
- 2013-07-15 KR KR1020227041256A patent/KR20220164068A/ko not_active Application Discontinuation
- 2013-07-15 CN CN202111361393.5A patent/CN114409596A/zh active Pending
- 2013-07-15 US US13/942,443 patent/US9115085B2/en active Active
- 2013-07-15 LT LTEP18189607.7T patent/LT3470397T/lt unknown
- 2013-07-15 KR KR1020217034322A patent/KR20210130849A/ko not_active Application Discontinuation
- 2013-07-15 CN CN202210791828.8A patent/CN115093370A/zh active Pending
- 2013-07-15 CN CN201310302481.7A patent/CN103539735B/zh active Active
- 2013-07-15 JP JP2015523160A patent/JP6491093B2/ja active Active
- 2013-07-15 IN IN262KON2015 patent/IN2015KN00262A/en unknown
- 2013-07-15 HR HRP20220182TT patent/HRP20220182T1/hr unknown
- 2013-07-15 CN CN201710546643.XA patent/CN107540607A/zh active Pending
- 2013-07-15 ES ES18189607T patent/ES2905898T3/es active Active
- 2013-07-15 RS RS20220121A patent/RS63122B1/sr unknown
- 2013-07-15 CN CN201710546191.5A patent/CN107501177B/zh active Active
- 2013-07-15 LT LTEP13740185.7T patent/LT2872488T/lt unknown
- 2013-07-15 KR KR1020157003613A patent/KR102149380B1/ko active IP Right Grant
- 2013-07-15 KR KR1020207024326A patent/KR102318720B1/ko active IP Right Grant
- 2013-07-15 ES ES13740185.7T patent/ES2689430T3/es active Active
- 2013-07-15 SI SI201331143T patent/SI2872488T1/sl unknown
- 2013-07-15 EP EP21212372.3A patent/EP4029854A1/en active Pending
- 2013-07-15 SG SG10202111314YA patent/SG10202111314YA/en unknown
- 2013-07-15 AU AU2013290438A patent/AU2013290438C1/en active Active
-
2015
- 2015-01-11 IL IL236626A patent/IL236626B/en active IP Right Grant
- 2015-07-21 US US14/805,345 patent/US9617218B2/en active Active
-
2017
- 2017-03-17 US US15/462,688 patent/US10118897B2/en active Active
- 2017-10-20 JP JP2017203509A patent/JP2018009034A/ja active Pending
-
2018
- 2018-02-28 HK HK18102870.1A patent/HK1243409A1/zh unknown
- 2018-10-11 US US16/158,242 patent/US20190276408A1/en not_active Abandoned
- 2018-10-24 HR HRP20181751TT patent/HRP20181751T1/hr unknown
- 2018-10-31 CY CY181101128T patent/CY1120805T1/el unknown
-
2019
- 2019-12-16 US US16/716,433 patent/US20200115344A1/en not_active Abandoned
-
2022
- 2022-02-14 CY CY20221100127T patent/CY1125155T1/el unknown
- 2022-06-15 FR FR22C1030C patent/FR22C1030I1/fr active Active
- 2022-06-20 LT LTPA2022510C patent/LTPA2022510I1/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200030I1 (hu) | Prolil hidroxiláz inhibitor kristályos alakjai | |
HRP20181751T1 (hr) | Kristalni oblici inhibitora prolil hidroksilaze | |
HK1257823A1 (zh) | 金屬酶抑制劑化合物 | |
HK1206743A1 (en) | 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors hif 4-- | |
HK1198163A1 (en) | Metalloenzyme inhibitor compounds | |
HK1198651A1 (en) | Metalloenzyme inhibitor compounds | |
EP2723730A4 (en) | METALLOENZYMHEMMERVERBINDUNGEN | |
HK1212333A1 (en) | Crystalline forms of a factor xia inhibitor xia | |
HK1206747A1 (en) | Crystalline forms of an hcv inhibitor hcv | |
EP2751117A4 (en) | METALLOENZYMHEMMERVERBINDUNGEN | |
EP2748160A4 (en) | INHIBITORY COMPOUNDS OF HEPATITIS C | |
EP2748167A4 (en) | INHIBITORY COMPOUNDS OF HEPATITIS C |